Prostate cancer screening may benefit some men who have survived colorectal cancer, but only after careful consideration of their age, overall health, and prior cancer treatments. A new clinical perspective highlights that while screening could be appropriate for carefully selected patients, the unique challenges of diagnosing and treating prostate cancer in this population require individualized discussion between doctors and patients.

Why Is Prostate Screening Different for Colorectal Cancer Survivors?

Men who have been treated for colorectal cancer face distinct obstacles when it comes to prostate cancer screening that don't apply to the general population. If a patient received pelvic radiation therapy during treatment for rectal cancer, their prostate-specific antigen (PSA) levels, a key marker used in screening, may be lower than expected. This means the standard PSA thresholds used to recommend biopsies in other men may not apply to them.

Additionally, some colorectal cancer surgeries create physical barriers to diagnosis. Patients who underwent an abdominoperineal resection, a procedure that removes the rectum entirely, cannot have a digital rectal examination or a transrectal ultrasound-guided biopsy, the most common diagnostic methods. Alternative biopsy approaches carry additional costs and risks that patients need to understand before proceeding.

Treatment options for prostate cancer are also limited in this population. Prior pelvic surgery or radiation therapy can increase the risk of serious side effects if radiation therapy is used to treat prostate cancer. Research from the Netherlands has shown that a history of abdominal surgery increases the risk of rectal toxicity from prostate radiation therapy, a complication that could affect quality of life.

Who Might Actually Benefit From Prostate Screening After Colorectal Cancer?

The decision to screen for prostate cancer in colorectal cancer survivors should depend on several key factors. Experts emphasize that age plays a critical role, and screening recommendations should not exceed those already established by major cancer organizations like the American Urological Association.

A younger, otherwise healthy 50-year-old man with a long life expectancy and elevated prostate cancer risk might be a reasonable candidate for screening, even if he has a history of stage III colon cancer, provided enough time has passed since his colorectal cancer treatment. In contrast, an older patient, even with early-stage colorectal cancer, is less likely to benefit from screening.

Recent advances in colorectal cancer treatment have significantly improved survival rates, which also factors into the decision. In landmark trials, patients with stage II colon cancer achieved a 6-year overall survival rate of 87%, while those with stage III disease reached 73%. For elderly patients specifically, the 5-year survival rate for stage II disease was 76%. These improved outcomes mean that more colorectal cancer survivors are living long enough to develop other cancers, making the prostate screening question more relevant than it once was.

How to Discuss Prostate Screening With Your Doctor After Colorectal Cancer

• Review Your Cancer History: Bring detailed records of your colorectal cancer treatment, including whether you received pelvic radiation therapy, what type of surgery you had, and how long ago treatment ended. This information directly affects screening recommendations.
• Assess Your Life Expectancy: Discuss your overall health, age, family history of prostate cancer, and any comorbidities with your doctor. Screening is most beneficial for men expected to live at least 10 to 15 more years.
• Understand the Unique Challenges: Ask your doctor to explain how your prior colorectal cancer treatment might affect PSA interpretation, biopsy options, and future prostate cancer treatment if cancer is found. This ensures you make an informed decision.
• Consider Individualized Prognostic Tools: Request that your doctor use tools like Adjuvant! Online, which analyzes survival data from the Surveillance, Epidemiology and End Results (SEER) database, to help estimate your colorectal cancer prognosis and inform the screening discussion.

The key message from experts is that one-size-fits-all screening recommendations do not apply to colorectal cancer survivors. Instead, the decision requires a personalized conversation that weighs the potential benefits of early prostate cancer detection against the specific risks and challenges posed by prior colorectal cancer therapy.

"It may be appropriate to offer prostate cancer screening to carefully selected men with a previous history of colorectal cancer. However, the risks and benefits of establishing the diagnosis in this setting, and the unique challenges of treatment, need to be considered and discussed with them," noted experts reviewing current evidence.

Clinical Perspective, ONCOLOGY Journal

For colorectal cancer survivors considering prostate screening, the most important step is having an honest, detailed conversation with an oncologist or urologist who understands both your cancer history and your individual health profile. This personalized approach helps ensure that screening decisions align with your values, life expectancy, and ability to tolerate potential complications.